Table 1.

Distribution of relapsed/not relapsed patients and mean level of miRNA expression according to selected covariates

RelapsedNot relapsed
n (%)n (%)miR-9miR-1miR-133amiR-150
Sex
 Men11 (100.0)24 (72.7)319.02193.8396.7537.7
 Women0 (0.0)9 (27.3)180.9186.5132.01752.8
P = 0.0849P = 0.6812P = 0.4459P = 0.9266P = 0.0358
Age
 <60 years8 (72.7)15 (46.9)310.8512.386.2542.4
 ≥60 years3 (27.3)17 (53.1)288.23777.7721.0896.1
P = 0.1753P = 0.5217P = 0.6463P = 0.6575P = 0.4025
Cancer site
 Tongue oral cavity5 (45.5)23 (69.7)149.9724.8110.0684.6
 Oropharynx Hypopharynx5 (45.5)6 (18.2)329.93425.2662.3499.5
 Larynx1 (9.0)4 (12.1)648.378.718.41452.2
P = 0.2104P = 0.3178P = 0.3296P = 0.5829P = 0.2347
cT
 T1–T23 (27.3)21 (65.6)209.0941.5169.3584.8
 T3–T48 (72.7)11 (34.7)341.22365.4446.6744.9
P = 0.0383P = 0.9737P = 0.0409P = 0.1021P = 0.9211
cN
 03 (27.3)13 (40.6)321.05360.71024.5626.5
 1–28 (72.7)19 (59.4)292.2432.072.5726.6
P = 0.4942P = 0.7667P = 0.4503P = 0.4409P = 0.7168
Adjuvant radio/chemotherapy
 No6 (54.6)26 (78.8)160.0638.9126.2489.1
 Yes5 (45.4)7 (21.2)391.62763.3513.9829.3
P = 0.1387P = 0.3709P = 0.9752P = 0.4672P = 0.4043
  • The significant differences are shown in bold.

    Abbreviations: cN, clinical evaluation of node status; cT, clinical evaluation of tumor size.